268 related articles for article (PubMed ID: 30124533)
1. Thyroid eye disease: what is new to know?
Li Z; Cestari DM; Fortin E
Curr Opin Ophthalmol; 2018 Nov; 29(6):528-534. PubMed ID: 30124533
[TBL] [Abstract][Full Text] [Related]
2. The eye and thyroid disease.
Kuriyan AE; Phipps RP; Feldon SE
Curr Opin Ophthalmol; 2008 Nov; 19(6):499-506. PubMed ID: 18854695
[TBL] [Abstract][Full Text] [Related]
3. [LIFESTYLE ADJUSTMENT AS THERAPEUTIC TOOL IN THYROID EYE DISEASE].
Vashdi I; Gur Z
Harefuah; 2022 Apr; 161(4):223-227. PubMed ID: 35466606
[TBL] [Abstract][Full Text] [Related]
4. Cigarette smoking and thyroid eye disease: a systematic review.
Thornton J; Kelly SP; Harrison RA; Edwards R
Eye (Lond); 2007 Sep; 21(9):1135-45. PubMed ID: 16980921
[TBL] [Abstract][Full Text] [Related]
5. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit.
Mellington FE; Dayan CM; Dickinson AJ; Hickey JL; MacEwen CJ; McLaren J; Perros P; Rose GE; Uddin J; Vaidya B; Foley P; Lazarus JH; Mitchell A; Ezra DG;
Orbit; 2017 Jun; 36(3):159-169. PubMed ID: 28296512
[TBL] [Abstract][Full Text] [Related]
6. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
Krassas GE
Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
[TBL] [Abstract][Full Text] [Related]
7. Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.
Yu CY; Ford RL; Wester ST; Shriver EM
Indian J Ophthalmol; 2022 Jul; 70(7):2335-2345. PubMed ID: 35791115
[TBL] [Abstract][Full Text] [Related]
8. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease.
Strianese D
Curr Opin Ophthalmol; 2017 Sep; 28(5):505-513. PubMed ID: 28700384
[TBL] [Abstract][Full Text] [Related]
9. Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment.
Johnson BT; Jameyfield E; Aakalu VK
Curr Opin Neurol; 2021 Feb; 34(1):116-121. PubMed ID: 33278144
[TBL] [Abstract][Full Text] [Related]
10. Bilateral versus unilateral thyroid eye disease.
Kashkouli MB; Kaghazkanani R; Heidari I; Ketabi N; Jam S; Azarnia S; Pakdel F
Indian J Ophthalmol; 2011; 59(5):363-6. PubMed ID: 21836341
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors of Thyroid Eye Disease.
Lee MH; Chin YH; Ng CH; Nistala KRY; Ow ZGW; Sundar G; Yang SP; Khoo CM
Endocr Pract; 2021 Mar; 27(3):245-253. PubMed ID: 33655885
[TBL] [Abstract][Full Text] [Related]
12. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
[TBL] [Abstract][Full Text] [Related]
13. Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease.
Heisel CJ; Riddering AL; Andrews CA; Kahana A
Ophthalmic Plast Reconstr Surg; 2020; 36(1):17-20. PubMed ID: 31568022
[TBL] [Abstract][Full Text] [Related]
14. Advances in the management of thyroid eye diseases: An overview.
Kumari R; Chandra Saha B
Int Ophthalmol; 2018 Oct; 38(5):2247-2255. PubMed ID: 28822031
[TBL] [Abstract][Full Text] [Related]
15. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiology of thyroid eye disease: implications for immunotherapy.
Douglas RS; Gupta S
Curr Opin Ophthalmol; 2011 Sep; 22(5):385-90. PubMed ID: 21730841
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease.
Strianese D
Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S56-S59. PubMed ID: 29923966
[TBL] [Abstract][Full Text] [Related]
18. Updates on the understanding and management of thyroid eye disease.
Men CJ; Kossler AL; Wester ST
Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
